WILMINGTON, N.C., June 14, 2011 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a pioneer in less invasive approaches to lumbar spine surgery, announced today that the 10,000th U.S. patient has recently been treated with its AxiaLIF lower lumbar fusion technology.
According to company records, the pivotal case was performed on June 11 by Serge Obukhoff, MD, at Pacific Hospital in Long Beach, CA. Dr. Obukhoff commented, "I am impressed by how much the technology has advanced since our first AxiaLIF surgery in March 2008. In today's surgery, we had the option to use the second-generation AxiaLIF 1L+ device, as well as TranS1's new inflatable bowel retractor, new disc space preparation tools and pedicle screws, none of which were available three years ago."
"The achievement of the 10,000 patient milestone demonstrates market acceptance of our technology and establishes AxiaLIF as a long-term participant in the lumbar spine fusion market," stated Ken Reali, President and CEO of TranS1 Inc. "Our ongoing R&D efforts are focused on the improvement of our instruments and implants and we continue to generate new clinical data that consistently demonstrates the safety and efficacy of our approach and implant."
About TranS1 Inc.
TranS1 is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine involving the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single and multilevel lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. TranS1 was founded in May 2000 and is headquartered in Wilmington, North Carolina. For more information, visit .
CONTACT: TranS1 Inc. Investors: Joe Slattery, Executive Vice-President and Chief Financial Officer 910-332-1700 Westwicke Partners Mark Klausner 443-213-0501 trans1@westwicke.com